15 Oct 2025
20:25 CEST |
GENEURO |
GeNeuro SA Postpones Publication of June 30, 2025 Half-Yearly Financial Report
|
20103010 Biotechnology |
Other subject |
15 Oct 2025
20:25 CEST |
GENEURO |
GeNeuro SA annonce le report de la publication de son rapport semestriel au 30 juin 2025
|
20103010 Biotechnology |
Other subject |
26 Sep 2025
18:36 CEST |
GENEURO |
GeNeuro SA annonce la prolongation de son sursis concordataire définitif
|
20103010 Biotechnology |
New |
26 Sep 2025
18:36 CEST |
GENEURO |
GeNeuro SA Announces the Extension of its Definitive Debt-Restructuring Moratorium
|
20103010 Biotechnology |
New |
16 Jul 2025
08:00 CEST |
GENEURO |
GeNeuro SA annonce la liquidation judiciaire de sa filiale française GeNeuro Innovation SAS
|
20103010 Biotechnology |
New |
16 Jul 2025
08:00 CEST |
GENEURO |
GeNeuro SA Announces the Liquidation of Its French Subsidiary GeNeuro Innovation SAS
|
20103010 Biotechnology |
New |
30 Jun 2025
19:37 CEST |
GENEURO |
Les actionnaires de GeNeuro approuvent l’ensemble des résolutions proposées à l’Assemblée Générale Extraordinaire
|
20103010 Biotechnology |
Legal |
30 Jun 2025
19:37 CEST |
GENEURO |
GeNeuro Announces Approval of All Resolutions Proposed at Extraordinary General Meeting
|
20103010 Biotechnology |
Legal |
12 Jun 2025
22:42 CEST |
GENEURO |
GeNeuro SA annonce l’ouverture d’une procédure de redressement judiciaire de sa filiale française GeNeuro Innovation SAS
|
20103010 Biotechnology |
Legal |
12 Jun 2025
22:42 CEST |
GENEURO |
GeNeuro SA Announces the Opening of Receivership Proceedings for Its French Subsidiary GeNeuro Innovation SAS
|
20103010 Biotechnology |
Legal |
10 Jun 2025
18:24 CEST |
GENEURO |
GeNeuro SA Announces an Extraordinary Shareholders’ Meeting on June 30, 2025
|
20103010 Biotechnology |
New |
10 Jun 2025
18:24 CEST |
GENEURO |
GeNeuro SA annonce la tenue d’une assemblée générale extraordinaire le 30 juin 2025
|
20103010 Biotechnology |
New |
27 May 2025
18:00 CEST |
GENEURO |
GeNeuro SA Announces Definitive Debt-Restructuring Moratorium
|
20103010 Biotechnology |
Legal |
27 May 2025
18:00 CEST |
GENEURO |
GeNeuro SA annonce le prononcé d’un sursis concordataire définitif
|
20103010 Biotechnology |
Legal |
12 May 2025
18:36 CEST |
GENEURO |
GeNeuro SA annonce le report de la publication des résultats annuels de la Société
|
20103010 Biotechnology |
Legal |
12 May 2025
18:36 CEST |
GENEURO |
GeNeuro SA Announces the Postponement of the Publication of the Company's 2024 Annual Results
|
20103010 Biotechnology |
Legal |
28 Jan 2025
18:08 CET |
GENEURO |
GeNeuro SA Announces Renewal of Provisional Debt-Restructuring Moratorium
|
20103010 Biotechnology |
New |
28 Jan 2025
18:08 CET |
GENEURO |
GeNeuro SA annonce la prolongation du sursis concordataire provisoire
|
20103010 Biotechnology |
New |
06 Dec 2024
18:30 CET |
GENEURO |
De nouvelles données soutenant une nouvelle approche de médecine de précision pour les patients atteints de SLA avec le GNK-301 de GeNeuro présentées lors du 35e Symposium international sur la SLA/MMN
|
20103010 Biotechnology |
New |
06 Dec 2024
18:30 CET |
GENEURO |
New Data Supporting a New Precision Medicine Approach for ALS Patients With GeNeuro’s GNK-301 Presented at the 35th International Symposium on ALS/MND
|
20103010 Biotechnology |
New |
30 Sep 2024
07:00 CEST |
GENEURO |
GeNeuro SA obtient l’ouverture d’une procédure de sursis concordataire
|
20103010 Biotechnology |
Legal |
30 Sep 2024
07:00 CEST |
GENEURO |
GeNeuro SA Obtains the Opening of Debt-Restructuring Proceedings
|
20103010 Biotechnology |
Legal |
19 Sep 2024
18:30 CEST |
GENEURO |
GeNeuro : Présentation de nouvelles données au congrès ECTRIMS 2025 à Copenhague montrant la réparation des effets neurodégénératifs de HERV-W par le Temelimab dans un modèle de SEP
|
20103010 Biotechnology |
New |
19 Sep 2024
18:30 CEST |
GENEURO |
GeNeuro: New Data Presented at the ECTRIMS 2025 Congress in Copenhagen Shows That Temelimab Rescues the Neurodegenerative Effects of HERV-W in an MS Model
|
20103010 Biotechnology |
New |
15 Jul 2024
07:00 CEST |
GENEURO |
GeNeuro Announces That It Submits a Request for a Debt Moratorium to the Geneva Court of First Instance
|
20103010 Biotechnology |
Other subject |
15 Jul 2024
07:00 CEST |
GENEURO |
GeNeuro annonce déposer une requête de sursis concordataire au Tribunal de première instance de Genève
|
20103010 Biotechnology |
Other subject |
10 Jul 2024
18:00 CEST |
GENEURO |
GeNeuro : Fin du contrat de liquidité conclu avec GILBERT DUPONT
|
20103010 Biotechnology |
Legal |
10 Jul 2024
18:00 CEST |
GENEURO |
GeNeuro SA: End of the Liquidity Contract With GILBERT DUPONT
|
20103010 Biotechnology |
Legal |
03 Jul 2024
17:45 CEST |
GENEURO |
Geneuro SA : Bilan semestriel du contrat de liquidité contracté avec la société de bourse Gilbert Dupont
|
20103010 Biotechnology |
Other subject |
03 Jul 2024
17:45 CEST |
GENEURO |
Geneuro SA: Half-Yearly Report on the Liquidity Contract with Gilbert Dupont
|
20103010 Biotechnology |
Other subject |
28 Jun 2024
07:00 CEST |
GENEURO |
GeNeuro annonce les résultats de l’essai GNC-501 dans le syndrome post-Covid-19
|
20103010 Biotechnology |
New establishment |
28 Jun 2024
07:00 CEST |
GENEURO |
GeNeuro Announces Results of the GNC-501 Study in Post-Covid-19 Syndrome
|
20103010 Biotechnology |
New establishment |
14 Jun 2024
18:30 CEST |
GENEURO |
GeNeuro Announces Approval of all Resolutions Proposed at 2024 Annual General Meeting
|
20103010 Biotechnology |
General meeting / Board Meeting |
14 Jun 2024
18:30 CEST |
GENEURO |
Les actionnaires de GeNeuro approuvent l’ensemble des résolutions proposées à l’Assemblée Générale Annuelle 2024
|
20103010 Biotechnology |
General meeting / Board Meeting |
29 May 2024
19:27 CEST |
GENEURO |
Availability of documents and information for the annual shareholders’ meeting of June 12, 2024
|
20103010 Biotechnology |
General meeting / Board Meeting |
29 May 2024
19:27 CEST |
GENEURO |
Modalités de mise à disposition des informations relatives à l’assemblée générale des actionnaires du 12 juin 2024
|
20103010 Biotechnology |
General meeting / Board Meeting |
16 May 2024
08:00 CEST |
GENEURO |
GeNeuro annonce la dernière visite du dernier patient dans son étude post-COVID et confirme que les principaux résultats seront disponibles à fin juin 2024
|
20103010 Biotechnology |
New |
16 May 2024
08:00 CEST |
GENEURO |
GeNeuro Announces Last Patient Last Visit in its Post-COVID Trial and Confirms Top-Line Results by End of June 2024
|
20103010 Biotechnology |
New |
02 May 2024
18:00 CEST |
GENEURO |
GeNeuro met à disposition son document universel de référence 2023
|
20103010 Biotechnology |
Legal |
02 May 2024
18:00 CEST |
GENEURO |
GeNeuro Publishes its 2024 Universal Registration Document
|
20103010 Biotechnology |
Legal |
30 Apr 2024
19:54 CEST |
GENEURO |
GeNeuro Reports 2023 Full-Year Results and Provides Corporate Update
|
20103010 Biotechnology |
Income |
30 Apr 2024
19:54 CEST |
GENEURO |
GeNeuro annonce ses résultats annuels 2023 et fait le point sur ses développements
|
20103010 Biotechnology |
Income |
20 Mar 2024
18:30 CET |
GENEURO |
Les actionnaires de GeNeuro approuvent l’ensemble des résolutions proposées à l’Assemblée Générale Extraordinaire du 18 mars 2024
|
20103010 Biotechnology |
General meeting / Board Meeting |
20 Mar 2024
18:30 CET |
GENEURO |
GeNeuro Announces Approval of all Resolutions Proposed at March 18, 2024, Extraordinary General Meeting
|
20103010 Biotechnology |
General meeting / Board Meeting |
03 Feb 2024
00:40 CET |
GENEURO |
GeNeuro annonce la mise à disposition d’un prospectus à l’occasion de l’admission d’actions nouvelles sur Euronext Paris
|
20103010 Biotechnology |
Legal |
02 Feb 2024
08:00 CET |
GENEURO |
GeNeuro Announces a Successful €5 Million Private Placement
|
20103010 Biotechnology |
Share introduction and issues |
02 Feb 2024
08:00 CET |
GENEURO |
GeNeuro annonce la réussite d’un placement privé de 5 millions d’euros
|
20103010 Biotechnology |
Share introduction and issues |
01 Feb 2024
17:55 CET |
GENEURO |
GeNeuro lance une offre avec engagement de souscription d’actionnaires existants et annonce sa position de trésorerie au 31 décembre 2023
|
20103010 Biotechnology |
Share introduction and issues |
01 Feb 2024
17:55 CET |
GENEURO |
GeNeuro Launches an Offering With a Commitment to Subscribe by Existing Shareholders and Announces Its Cash Position at December 31, 2023
|
20103010 Biotechnology |
Share introduction and issues |
05 Jan 2024
18:00 CET |
GENEURO |
GeNeuro Names Anke Post as Chief Medical Officer, Following Retirement of David Leppert who Becomes a Consultant to GeNeuro
|
20103010 Biotechnology |
New |